文献速递炎症性肠病消化内镜

胶囊通畅性检查:静止期克罗恩病患者长期结局的新型独立预测因素

Patency Capsule: A Novel Independent Predictor for Long-Term Outcomes Among Patients With Quiescent Crohn's Disease.
PubMed 文献 · Am J Gastroenterol · 2022-12-23

该研究对2项前瞻性队列研究进行事后分析,纳入190例接受胶囊通畅性检查(PC)的成人静止期小肠克罗恩病患者,比较PC未通过组与通过组的长期结局。PC未通过组主要复合结局(手术或内镜扩张)发生率显著更高(21.3% vs 1.4%,HR 20.3,95%CI 4.4-93.7,P<0.001),且独立于CD表型。

要点

  • PC未通过组主要复合结局发生率为21.3%,通过组为1.4%,HR 20.3(95%CI 4.4-93.7,P<0.001)。
  • 在狭窄型表型患者(n=73)中,PC未通过仍预测长期复合结局(HR 8.68,95%CI 1.72-43.68,P=0.002)。
  • 190例中仅1例PC未通过患者出现48小时自限性轻度症状。

核心结论

  • 临床稳定的克罗恩病患者中,PC未通过者长期临床结局较PC通过者更差,且独立于CD表型。
  • 单独PC可作为新型、安全、可负担的预后检查,识别未来临床结局更差的静止期CD患者。

研究设计与样本

  • 对2项前瞻性队列研究的事后分析,纳入2013年至2020年间接受PC的成人静止期小肠克罗恩病患者。
  • 共纳入190例患者,其中PC未通过47例,PC通过143例,中位随访34.12个月。

主要发现

  • PC未通过组主要复合结局(随访期间需肠道手术或内镜扩张)发生率为21.3%,PC通过组为1.4%(HR 20.3,95%CI 4.4-93.7,P<0.001)。
  • PC未通过组肠道手术发生率为14.9%,PC通过组为0.70%(P<0.001)。
  • PC未通过组内镜扩张发生率为14.9%,PC通过组为0.70%(P<0.001)。
  • PC未通过组入院发生率为23.3%,PC通过组为5.7%(P<0.001)。
  • PC未通过组临床 flare 发生率为43.9%,PC通过组为27.7%(P=0.005)。

关键数值与推荐

  • 在仅限狭窄型表型患者(n=73)的敏感性分析中,PC未通过仍预测长期复合结局(HR 8.68,95%CI 1.72-43.68,P=0.002)。
  • PC未通过是手术和/或内镜扩张的唯一统计学显著因素,无论基线是否为B2/B3表型。
  • 190例摄入PC的患者中,仅1例PC未通过患者出现48小时自限性轻度症状。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Patency capsule (PC) is a recommended procedure to rule out small bowel stenosis before video capsule endoscopy (VCE). We examined future clinical outcomes among patients with a failed PC vs patients in whom the PC had passed (passed PC). METHODS: A post hoc analysis of 2 prospective cohort studies of adult patients with quiescent small bowel Crohn's disease (CD) who underwent PC between 2013 and 2020. The primary composite outcome was the need for intestinal surgery or endoscopic dilation during follow-up in patients with or without a failed PC. RESULTS: A total of 190 patients were included (47: failed PC and 143: passed PC, median follow-up 34.12 months). Patients with a failed PC had higher rates of the primary composite outcome (21.3% vs 1.4%, hazard ratio [HR] 20.3, 95% confidence interval [CI] 4.4-93.7, P < 0.001) and also secondary outcomes including intestinal surgery (14.9% vs 0.70%, P < 0.001), endoscopic dilation (14.9% vs 0.70%, P < 0.001), admissions (23.3% vs 5.7%, P < 0.001), and clinical flares (43.9% vs 27.7%, P = 0.005) during follow-up compared with controls. Failed PC was the only statistically significant factor for surgery and/or endoscopic dilation, regardless of a B2/B3 phenotype at baseline. In sensitivity analyses restricted only to patients with a stricturing phenotype (n = 73), a failed PC still predicted the long-term composite outcome (HR 8.68, 95% CI 1.72-43.68, P = 0.002). Of the 190 patients ingesting a PC, only 1 patient with a failed PC had 48 hours of self-limiting mild symptoms. DISCUSSION: Patients with clinically stable CD with a failed PC have worse long-term clinical outcomes than those without, independently of the CD phenotype. Standalone PC may serve as a novel, safe, and affordable prognostic examination to identify patients with quiescent CD who have a higher risk for future worse clinical outcomes.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Ukashi O, Kopylov U, Ungar B, et al. Patency Capsule: A Novel Independent Predictor for Long-Term Outcomes Among Patients With Quiescent Crohn's Disease. Am J Gastroenterol. 2022. PMID: 36563317. doi:10.14309/ajg.0000000000002118

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。